###begin article-title 0
Paraoxonase gene polymorphisms and haplotype analysis in a stroke population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 13 16 13 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
Paraoxonase (PON) has anti-atherogenic activity due to its protective function against low density lipoprotein (LDL) oxidation. Alteration of enzyme activity due to polymorphisms in the PON genes may influence the development of atheroma and thus affect stroke risk. Three PON genes (PON1, PON2 and PON3) have been identifiedand mapped to chromosome 7.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 523 527 523 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 579 583 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
We looked at the distribution of paraoxonase polymorphisms and haplotype arrangement in 397 Caucasian ischaemic stroke patients and 405 controls. We investigated 6 different common single nucleotide polymorphisms (SNP) in PON genes; two substitutions in PON1 ["A/G": Gln (Q)/Arg (R)] at codon 192 and ["T/A": Leu (L)/Met (M)] at codon 55, two in PON2 at codon 311 ["G/A": Cys (C)/Ser (S)] and codon 148 ["C/G": Ala (A)/Gly (G)] and two SNPs, both "A" to "G" substitutions, in PON3 - intronic rs2074353, which we designated PON3-1 and [Ala (A)/Ala (A)] at codon 99, designated as PON3-3. Dynamic Allele Specific Hybridisation (DASH) was used as the genotyping assay. Haplotype analysis was performed using both PHASE and EHPLUS programs.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
Genotype and allele frequencies were similar in cases and controls. Lipid profiles were not influenced by PON genotype. Haplotype frequencies for the six loci (PON2-148, PON2-311, PON3-3, PON3-1, PON1-55 and PON1-192) were estimated. Comparison of the two programs showed a significant difference in haplotype arrangements with EHPLUS (p-value = 0.005) but not with PHASE Ver.2 (p-value = 0.12). The 112211 (1 = frequent allele, 2 = rare allele) haplotype arrangement was commoner in cases than controls (p = 0.015), and the 111121 haplotype was commoner in controls (p = 0.006).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our study did not identify a role for individual paraoxonase gene polymorphisms in the pathogenesis of ischaemic stroke. Findings of haplotype differences should be confirmed in large scale studies. The importance of using a well-validated haplotype analysis program is also underlined.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 631 635 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 649 653 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 805 806 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 807 808 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Ischaemic stroke is a complex trait, with genetic influences likely to work through various risk factors for cerebrovascular disease. Hypertension and dyslipidemia are known to influence atherosclerosis and thus predispose to ischaemic stroke. Although lipids are a weaker risk factor for stroke than blood pressure or age, hyperlipidemia contributes to stroke risk [1], while lipid lowering therapy significantly reduces the risk of stroke [2]. Low HDL has also been reported as a risk factor for ischaemic stroke [3]. Genes involved in lipid metabolism have been previously studied in the stroke population. Some studies suggest APOE*epsilon4 and APOE*epsilon2 alleles are associated with higher risk and lower risk of ischaemic stroke respectively, although this has not been confirmed in all studies [4,5].
###end p 11
###begin p 12
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Paraoxonase, a 45 kDa glycoprotein, is well known for its ability to detoxify organophosphates [6]. The process of atherosclerosis is thought to begin with inflammatory changes at the endothelial level, and oxidated LDL is believed to be pro-inflammatory. Oxidated lipids have also been associated with progression of carotid atherosclerosis [7,8]. As an HDL associated protein, paraoxonase protects LDL against oxidation [9], and thus may protect against atherosclerosis [10].
###end p 12
###begin p 13
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 535 543 535 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON 192 </italic>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 735 740 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 746 750 746 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 823 827 823 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 924 928 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 1071 1075 1071 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 905 913 <span type="species:ncbi:9606">patients</span>
The paraoxonase gene maps to chromosome 7 (q21-23) and has three isoforms, PON1, PON2 and PON3 [11]. Some studies suggest PON polymorphisms might predispose to CHD or ischaemic stroke [12-14], while other studies are less conclusive [15]. PON1 has two common polymorphisms at codon 192 [A/G: Gln (Q)/Arg (R)] and 55 [T/A: Leu(L)/Met (M)]. These have been shown to correlate with enzyme activity [16,17]. Increased enzyme activity has been associated with higher HDL levels in some populations [18,19], but not in all studies [20]. The PON 192 and 55 polymorphisms have been associated with risk of ischaemic stroke in a small study of younger adults [13] and older patients respectively [21]. There are two common polymorphisms of the PON2 gene, PON2-148 [C/G: Ala (A)/Gly (G)] and PON2-311 [C/G: Cys (C)/Ser (S)], and the PON2-148 "G" (G variant) is associated with higher fasting blood glucose in NIDDM patients [22]. The PON2-311 "G" (S allele) has been associated with coronary artery diseases in different populations [23]. PON3 is thought to have a similar role to PON1[24].
###end p 13
###begin p 14
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
The purpose of this study was to assess the distribution of polymorphisms of the PON1, PON2 and PON3 genes in well-phenotyped patients with ischaemic stroke and matched control subjects, and to expand on previous studies by examining haplotype distribution in these samples. We also examined the association between genotype and full lipid profile for a subgroup of controls.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 526 530 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
After ethical committee approval and informed consent, 397 Caucasian patients with a diagnosis of ischemic stroke were recruited over a period of 3 years. Four hundred and five Caucasian individuals from the same region, without any clinical cerebrovascular or overt cardiovascular disease and matched for age and sex were used as controls. For a subgroup of controls (n = 181) detailed lipid parameters including total cholesterol, VLDL-Cholesterol, VLDL Triglyceride, IDL, LDL, HDL2, HDL3 were available for comparison with PON genotypes.
###end p 17
###begin p 18
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
On the basis of clinical, laboratory and radiological parameters, all stroke cases were classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria [25] to determine stroke subtype (Table 1).
###end p 18
###begin p 19
###xml 78 86 <span type="species:ncbi:9606">patients</span>
TOAST (Trial of Org 10172 in Acute Stroke Treatment) Classification of stroke patients
###end p 19
###begin title 20
Markers and genotyping
###end title 20
###begin p 21
###xml 31 35 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 146 149 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
DNA was extracted using Nucleon(R) DNA extraction kits. 5-10 ng DNA was amplified through Hot Start PCR protocol using Immolase Taq DNA polymerase(R). We used different sets of primers for each SNP as follows:
###end p 21
###begin p 22
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
1-PON1-192 (A/G):
###end p 22
###begin p 23
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
PON1-192F: 5'-biotin-CTATTTTCTTGACCCCTACTTA-3'
###end p 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
PON1-192R: 5'-CGCTAAACCCAAATACATCTCC-3'
###end p 24
###begin p 25
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
2-PON1-55 (T/A):
###end p 25
###begin p 26
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
PON1-55F: 5'-biotin-CTGACAGAAACTGGCTCTGAAG-3'
###end p 26
###begin p 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
PON1-55R: 5'-AAGCCAGTCCATTAGGTAGTAT-3'
###end p 27
###begin p 28
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
3-PON2-311 (C/G):
###end p 28
###begin p 29
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
PON2-311F: 5'-biotin-GGTTCTCCGCATCCAGAACATT-3'
###end p 29
###begin p 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
PON2-311R: 5'-AACTGTAGTCACTGTAGGCTTCTC-3'
###end p 30
###begin p 31
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
4-PON2-148 (C/G):
###end p 31
###begin p 32
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
PON2-148F: 5'-AGTGGAAATTTTTAAATTTGAAG-3'
###end p 32
###begin p 33
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
PON2-148R: 5'-biotin-ACTGTTTTCAGATGCAACAGAGA-3'
###end p 33
###begin p 34
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
5-PON3-rs2074353 (PON3-1, A/G):
###end p 34
###begin p 35
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3b-2074353F: 5'-biotin-TCTTCCTTTGTAGTGTGTTAGGAA-3'
###end p 35
###begin p 36
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3-2074353R: 5'-AATTTTTACATAACTCTTGAAACA-3'
###end p 36
###begin p 37
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
6-PON3-rs2375003 (PON3-2, C/T):
###end p 37
###begin p 38
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3b-2375003F: 5'-biotin-CTGATCCCATGTAGATTAAATA-3'
###end p 38
###begin p 39
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3-2375003R: 5'-CGCTAGAAATCAGTGGTGGATT-3'
###end p 39
###begin p 40
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
7-PON3-rs1053275 (PON3-3, A/G):
###end p 40
###begin p 41
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3b-1053275F: 5'-biotin-TGTCAAATCCACCACTGATTTCTA-3'
###end p 41
###begin p 42
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
PON3-1053275R: 5'-GAACAAAACCCAAGGGCACAAG-3'
###end p 42
###begin p 43
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
Of the three PON3 SNPs, only two SNPs [rs2074353 (PON3-1, A/G) and rs1053275 (PON3-3, A/G)] were confirmed in our population, with genotype frequencies in Hardy Weinberg equilibrium. All other SNPs were also in Hardy Weinberg equilibrium.
###end p 43
###begin p 44
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Genotyping assays for determining different alleles were based on the Dynamic Allele Specific Hybridisation (DASH) technique as described by the developers [26].
###end p 44
###begin title 45
Data analysis
###end title 45
###begin p 46
###xml 77 79 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 333 337 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 343 347 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 352 356 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 360 364 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 368 372 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 380 384 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 507 509 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 510 512 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Association between markers and disease phenotype was tested with Pearson chi2 test. Multiple Logistic Regression was used to adjust for differences between samples in age, sex, smoking and hypertension. ANOVA was used to test for associations between lipid profiles and allelic distribution. Haplotype frequencies for the six loci (PON2-148, PON2-311 PON3-3, PON3-1, PON1-55 and PON1-192) were estimated for cases and controls, using and comparing two different validated programs: EHPLUS and PHASE Ver.2 [27,28].
###end p 46
###begin title 47
Results
###end title 47
###begin p 48
###xml 42 43 42 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Demographic parameters are shown in Table 2. Allele frequency for the six PON alleles investigated is shown in Table 3.
###end p 48
###begin p 49
Demographic parameters of cases and controls:
###end p 49
###begin p 50
* Non significant differences between cases and controls.
###end p 50
###begin p 51
** History of diabetes or confirmed laboratory diagnosis.
###end p 51
###begin p 52
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
Allele Frequencies of 6 SNPs in PON2, PON3 &PON1 genes
###end p 52
###begin p 53
* Adjusted for age, sex and hypertension.
###end p 53
###begin p 54
There was no significant difference between cases and controls by sex in genotype and allele frequencies. There was no significant difference in genotype and allele frequencies between cases and controls in terms of age stratification (>/=65 and <65 years).
###end p 54
###begin p 55
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
There was no significant difference in genotype or allele frequencies between cases and controls in the SVD group or LVD group, other than a small association between the GG genotype of PON3 and females with LVD (p = 0.03, OR = 2). PON2-311 "CC" genotype (SS variant) was higher in male cardioembolic (CE) stroke patients than in male controls (p = 0.03, OR = 2.05).
###end p 55
###begin p 56
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3</italic>
There was no association between lipid profile (LDL, HDL, total cholesterol/HDL ratio or triglycerides) and PON genotype in the stroke population. We also studied the association between PON genotype and full lipid profile in 181 of the controls. No differences were found in VLDL-Cholesterol, IDL, LDL, HDL2, HDL3, and total cholesterol concentrations in females or males between different genotypes of PON1-192, PON1-55, PON2-148 or PON3-1. VLDL-Triglyceride was higher in females with "GG" PON3-3 genotype (VLDL: AA genotype 69.8, "AG" genotype 77.8, "GG" genotype 116.0; p = 0.036).
###end p 56
###begin p 57
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Haplotype analysis was performed using PHASE version 2.02 and EHPLUS programs. The PHASE program [27], resulted in reconstruction of 16 different haplotypes in cases and controls. Overall haplotype frequencies in cases and controls were not significantly different (p = 0.19). However, some individual haplotypes were more frequent in one group than the other. Overall, the 112211 haplotype (1= frequent allele, 2= rare allele) was present at a higher frequency among cases than controls (16.62% vs 12.35%, p-value = 0.015, OR = 1.42 (1.07-1.87)). In contrast, 111121 was less frequent in cases than in controls (2.27% vs 4.81%, p = 0.006, OR = 0.46 (0.26-0.81)). There were also some differences in haplotype combination (genotype distribution) between cases and controls as follows: the "112211, 112221" haplotype (cases 10.6%, controls 5.2%: p = 0.005), the "111111, 112221" haplotype (cases 4%, controls 7.9%: p = 0.023).
###end p 57
###begin p 58
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
We repeated analyses using EHPLUS [28] to compare haplotype arrangements in cases and controls. With this method, there was a significant difference (p = 0.005, df, 63) between groups. The most frequent haplotype in cases was 112211 and in controls 111111, while with PHASE2 the commonest haplotype for both groups was 112221. The EHPLUS program generated 64 different haplotypes both in cases and controls but only 32 had a frequency of more than 1%.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2 </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 323 327 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 862 866 862 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 950 954 950 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1087 1091 1087 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1169 1171 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1256 1261 1256 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 728 736 <span type="species:ncbi:9606">patients</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
PON1 and PON2 are possible candidate genes for atherosclerotic diseases, especially coronary heart disease (CHD), but findings are inconsistent. In a recent meta-analysis of 43 studies [29], the 5 largest studies estimated the per-allele risk ratio at 1.05 for PON1-192 R (B) allele and combined analyses of studies of the PON1-55 M and PON2-311 C variants showed no significant overall associations with CHD. This differs from a recent study [30], not included in the meta-analysis, which suggested that the picture remains complicated. While there have been fewer studies in ischaemic stroke, there is some evidence of a role for the PON1-192 RR (BB) genotype and also for the PON1 (C-107T) allele in younger ischaemic stroke patients [13,14,31]. A recently published study of 81 stroke patients and 2053 controls from the CARE study also suggested a role for PON1-192 in predisposing to stroke, with no association with polymorphisms of the other PON genes. In contrast to this study, haplotype analysis or stroke subtyping was not performed [32]. There is evidence that paraoxonase (PON1) phenotype may predict vascular disease more accurately than genotype alone [33]. Due to logistical constraints in the current study it was not possible to measure PON1 phenotype, but future vascular studies should consider this.
###end p 60
###begin p 61
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
As there are ethical difficulties in gaining consent from incapacitated individuals, this is not a study based on incident stroke. It is acknowledged therefore that patients with more severe stroke may not be included. However, the TOAST classification has similar distribution to other studies. The distribution of other vascular risk factors shows that these are high risk individuals. They form a subgroup of a Scottish stroke population which has been demonstrated to have an association with 5-lipoxygenase activating protein, an important mediator of the activity of cellular 5-Lipoxygenase (5-LO) which is a key enzyme in the biosynthesis of leukotrienes, and may thus be involved in atherosclerosis by proinflammatory mechanisms [34]. While a large number of individuals were unclassifiable by TOAST criteria, they all had CT evidence of ischaemic stroke. Individuals with cardioembolic stroke were also included. While these individuals may have a different underlying mechanism for their event, the role of oxidative stress through lipids driving atherothrombosis is likely to underlie the cardiac disease in most of these individuals.
###end p 61
###begin p 62
Other than weak associations in small subgroups (females with LVD stroke, males with CE stroke), our study found no significance in overall allele or genotype frequency, although haplotype analysis suggests that the combination of certain alleles may increase or decrease the risk of ischaemic stroke in the whole population or in some specific subtypes. These results should be interpreted with caution due to the small numbers of individuals with specific haplotypes, but reinforces the need for very large scale studies to provide a definitive answer.
###end p 62
###begin p 63
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
Although there are several programs based on different methods that can infer haplotypes, there is no consensus as to which method is the best [35]. Most programs, including EHPLUS, a modified version of EH developed by Ott, use the EM (Expectation-Maximisation) algorithm [28,35]. The program ignores all partial or missing genotype data so that the algorithm uses the full set of available data.
###end p 63
###begin p 64
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
The PHASE program is based on coalescent models and uses Markov chain Monte Carlo methods [27,35]. These algorithms use a population genetics model to estimate different haplotype patterns, so a haplotype that is more similar to the commonly observed haplotype patterns is more likely to be inferred.
###end p 64
###begin p 65
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
While the haplotype analysis is an important component of association studies in complex diseases [36], and the different computational methods have their individual strengths and weaknesses, significant haplotype differences in the absence of genotypic or allelic differences are difficult to interpret [35]. Our study highlights this further since one method (EHPLUS) suggests a statistically significant difference while PHSE fails to demonstrate an overall significant difference. It remains unclear which method is superior, but PHASE is believed to be more reliable for larger numbers of markers [35]. However, the level of significance is modest and could have arisen by chance.
###end p 65
###begin p 66
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1 </italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON3 </italic>
In some genetic isolates certain PON genotypes can be associated with variation in plasma lipoproteins levels including LDL, HDL and total cholesterol [37-39]. In addition the physical relationship of PON1 with HDL and the existence of cholesterol pathway regulatory elements at the PON1 locus suggest a further relationship of PON1 with lipoproteins, which may contribute to its role of vascular diseases [40]. However, apart from a minor correlation between VLDL-Triglyceride and PON3 genotypes in female, we did not replicate these differences in our out-bred Scottish population.
###end p 66
###begin title 67
Conclusion
###end title 67
###begin p 68
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON </italic>
In conclusion, we found no significant genotypic or allelic frequency differences between stroke cases and controls for any of the structural polymorphisms of the PON genes tested. We identified specific haplotypes which may influence stroke risk in our population. Further work is required in large cohorts to determine whether these differences are real or have arisen by chance.
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The author(s) declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
AP participated in study design, carried out the genotyping and the statistical analyses and drafted the manuscript. HRA and JC helped with sample preparation LW and DS contributed to the study design, sample collection and helped draft the manuscript. AC helped with study design and commented on the manuscript. MJM contributed to study design, coordinated recruitment and drafted the manuscript. Authors read and approved the final manuscript.
###end p 72
###begin title 73
Pre-publication history
###end title 73
###begin p 74
The pre-publication history for this paper can be accessed here:
###end p 74
###begin p 75

###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
We would like to thank Mashad University of Medical Sciences, Mashad, Iran and the Iranian Ministry of Health for their financial support. Lawrence Whalley holds a career development award from the Wellcome Trust who supported collection of control subject data.
###end p 77
###begin article-title 78
Status of lipids as a risk factor for stroke
###end article-title 78
###begin article-title 79
###xml 80 86 <span type="species:ncbi:9606">people</span>
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
###end article-title 79
###begin article-title 80
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Serum lipids in young patients with ischaemic stroke: a case-control study
###end article-title 80
###begin article-title 81
The Apolipoprotein E and beta-fibrinogen G/A-455 Gene Polymorphisms Are Associated With Ischemic Stroke Involving Large-Vessel Disease
###end article-title 81
###begin article-title 82
Lack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population
###end article-title 82
###begin article-title 83
###xml 79 84 <span type="species:ncbi:9606">human</span>
The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism
###end article-title 83
###begin article-title 84
Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview
###end article-title 84
###begin article-title 85
Lipoprotein Oxidation and Progression of Carotid Atherosclerosis
###end article-title 85
###begin article-title 86
###xml 207 212 <span type="species:ncbi:9606">Human</span>
Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities : Selective Action of Human Paraoxonase Allozymes Q and R
###end article-title 86
###begin article-title 87
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
###end article-title 87
###begin article-title 88
###xml 4 9 <span type="species:ncbi:9606">Human</span>
The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is One Member of a Multigene Family
###end article-title 88
###begin article-title 89
###xml 78 83 <span type="species:ncbi:9606">human</span>
Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus
###end article-title 89
###begin article-title 90
Paraoxonase 192 Gln->Arg Polymorphism: An Independent Risk Factor for Nonfatal Arterial Ischemic Stroke Among Young Adults
###end article-title 90
###begin article-title 91
The Combined Effect of Paraoxonase Promoter and Coding Region Polymorphisms on the Risk of Arterial Ischemic Stroke Among Young Adults
###end article-title 91
###begin article-title 92
Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus
###end article-title 92
###begin article-title 93
###xml 27 32 <span type="species:ncbi:9606">human</span>
The molecular basis of the human serum paraoxonase activity polymorphism
###end article-title 93
###begin article-title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Serum Paraoxonase
###end article-title 94
###begin article-title 95
R192Q paraoxonase gene variant is associated with a change in HDL-cholesterol level during dietary caloric restriction in nondiabetic healthy males
###end article-title 95
###begin article-title 96
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
###end article-title 96
###begin article-title 97
Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL
###end article-title 97
###begin article-title 98
MRI Cerebral White Matter Lesions and Paraoxonase PON1 Polymorphisms : Three-Year Follow-Up of the Austrian Stroke Prevention Study
###end article-title 98
###begin article-title 99
Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus
###end article-title 99
###begin article-title 100
Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population
###end article-title 100
###begin article-title 101
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids
###end article-title 101
###begin article-title 102
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment
###end article-title 102
###begin article-title 103
Robust and Accurate Single Nucleotide Polymorphism Genotyping by Dynamic Allele-Specific Hybridization (DASH): Design Criteria and Assay Validation
###end article-title 103
###begin article-title 104
A new statistical method for haplotype reconstruction from population data
###end article-title 104
###begin article-title 105
Model-Free Analysis and Permutation Tests for Allelic Associations
###end article-title 105
###begin article-title 106
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II
###end article-title 107
###begin article-title 108
Paraoxonase Polymorphisms and the Risk of Arterial Ischemic Stroke among Young Adults
###end article-title 108
###begin article-title 109
Evaluation of the Paraoxonases as Candidate Genes for Stroke: Gln192Arg Polymorphism in the Paraoxonase 1 Gene Is Associated With Increased Risk of Stroke
###end article-title 109
###begin article-title 110
Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype
###end article-title 110
###begin article-title 111
Association of the Gene Encoding 5-Lipoxygenase Activating Protein to Stroke Replicated in a Scottish Population.
###end article-title 111
###begin article-title 112
Haplotype analysis in population genetics and association studies
###end article-title 112
###begin article-title 113
Candidate genes, association studies and haplotype analysis in the search for the genetic basis of hypertension
###end article-title 113
###begin article-title 114
Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
###end article-title 114
###begin article-title 115
Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations
###end article-title 115
###begin article-title 116
A Polymorphism of the Paraoxonase Gene Associated With Variation in Plasma Lipoproteins in a Genetic Isolate
###end article-title 116
###begin article-title 117
Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase: A Role for Sterol Regulatory Element-Binding Protein-2
###end article-title 117

